Pages that link to "Q80837269"

The following pages link to Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat (Q80837269):

Displaying 30 items.

• Diabetic Cardiovascular Disease Induced by Oxidative Stress (Q26778017) (← links)
• Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy (Q26799863) (← links)
• Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies (Q27002459) (← links)
• Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism (Q27333630) (← links)
• FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy (Q28546854) (← links)
• Role of transcytolemmal water-exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease (Q30577730) (← links)
• 3′,4′-Dihydroxyflavonol Antioxidant Attenuates Diastolic Dysfunction and Cardiac Remodeling in Streptozotocin-Induced Diabetic m(Ren2)27 Rats (Q33987863) (← links)
• Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia. (Q35206048) (← links)
• N-Acetyl Cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition (Q35737823) (← links)
• Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension (Q35875059) (← links)
• Comparison between myocardial infarction and diabetes mellitus damage caused angiogenesis or energy metabolism (Q36511531) (← links)
• Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. (Q37088282) (← links)
• The therapeutic effect of Rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end‐stage hypertension in rats (Q37294951) (← links)
• Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor‐β (Q37924999) (← links)
• The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy (Q38335812) (← links)
• High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy (Q38989355) (← links)
• Insights for Oxidative Stress and mTOR Signaling in Myocardial Ischemia/Reperfusion Injury under Diabetes. (Q39180915) (← links)
• Suppression of NLRP3 Inflammasome Activation Ameliorates Chronic Kidney Disease-Induced Cardiac Fibrosis and Diastolic Dysfunction (Q39612410) (← links)
• Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression (Q42257917) (← links)
• Insulin restores myocardial presynaptic sympathetic neuronal integrity in insulin-resistant diabetic rats (Q44094316) (← links)
• Myocardial transcription factors in diastolic dysfunction: clues for model systems and disease (Q48273909) (← links)
• Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition". (Q49203906) (← links)
• Early diabetes treatment does not prevent sympathetic dysinnervation in the streptozotocin diabetic rat heart. (Q53063989) (← links)
• Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. (Q55457178) (← links)
• Diabetic cardiomyopathy (Q57186141) (← links)
• Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control (Q58698076) (← links)
• Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction (Q64105820) (← links)
• Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy (Q83346106) (← links)
• Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation (Q88813374) (← links)
• Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction (Q89608544) (← links)